Literature DB >> 15364262

Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.

P Wutzler1, K-D Kossow, H Lode, B R Ruf, H Scholz, G E Vogel.   

Abstract

Antiviral drugs are a valuable supplementation to vaccines for the control and prevention of influenza. In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved. Amantadine and oseltamivir are also licensed for prophylactic use. On behalf of the Paul-Ehrlich-Society of Germany and the German Association for the Control of Virus Diseases, as two independent scientific societies, the first consensus Conference on the Antiviral Treatment and Prophylaxis of Influenza was held in June 2002. Based on the available data of clinical studies an expert group developed the following recommendations for the appropriate clinical use of the antiviral drugs: (1) since oseltamivir (orally administered) and zanamivir (administered by inhalation) have apparently similar clinical efficacy both drugs can be used alternatively for treatment. (2) Amantadine is not an alternative to the neuraminidase (NA) inhibitors because it is not effective against influenza B viruses, it frequently selects resistant virus mutants and it can cause adverse events. (3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting not longer than 48 h. (4) Immunocompetent patients with a non-febrile illness and patients with a symptom history of more than 2 days should not be treated with antiviral drugs. (5) Although there are no data from clinical trials immunocompromised patients should also be treated when influenza has been diagnosed. (6) The prophylactic use of antiviral drugs can be recommended for persons with close contact to acutely ill persons and no recent vaccination against influenza. (7) The use of anti-influenza drugs have to be considered for prophylaxis in pandemics. A precondition for the adequate use of anti-influenza drugs in the primary medical care is the timely information on the local influenza situation delivered by surveillance systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364262     DOI: 10.1016/j.jcv.2004.05.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Antiviral activity of the effective monomers from Folium Isatidis against influenza virus in vivo.

Authors:  Zhao Liu; Zhan-qiu Yang; Hong Xiao
Journal:  Virol Sin       Date:  2011-01-10       Impact factor: 4.327

2.  Oseltamivir prophylaxis in controlling influenza outbreak in nursing homes: a comparison between three different approaches.

Authors:  N Gorišek Miksić; T Uršič; Z Simonović; L Lusa; P Lobnik Rojko; M Petrovec; F Strle
Journal:  Infection       Date:  2014-11-18       Impact factor: 3.553

Review 3.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

4.  Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.

Authors:  Hana M Dobrovolny; Catherine A A Beauchemin
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

5.  Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model.

Authors:  Ching-Tai Huang; Chen-Yiu Hung; Tse-Ching Chen; Chun-Yen Lin; Yung-Chang Lin; Chia-Shiang Chang; Yueh-Chia He; Yu-Lin Huang; Avijit Dutta
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.